The Supreme Court of India has barred Mumbai-based Glenmark Pharmaceuticals from making and selling generic versions of U.S. drugmaker Merck's diabetes drugs, Januvia and Janumet.
India's Supreme Court -- widely seen as biased in favor of boosting the local generic drugs industry -- did state in court documents that Glenmark is permitted to continue to sell existing inventory of the Merck drugs.
Merck brought the lawsuit against Glenmark in 2013 for infringing a patent it has on sitagliptin, the API used in Januvia and Janumet.
Read the Reuters article
